Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers

NCT01280201 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.

NCT NCT01280201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01280201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2011
Completion date
March 15, 2015
Enrollment
44 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic neuroendocrine tumors